Losartan FDA Approval History

Original Approval: April 1995

Losartan potassium received FDA approval on April 14, 1995, under NDA 020386, becoming the first drug in the ARB class to reach the U.S. market. The approval covered treatment of hypertension in adults, and Merck & Co. marketed it under the brand name Cozaar.

The pharmacologic rationale was straightforward. Angiotensin-converting enzyme (ACE) inhibitors had proven cardiovascular benefit but caused a persistent dry cough in roughly 5% to 35% of patients, driven by bradykinin accumulation. Losartan offered a mechanistically distinct approach: selective blockade of the angiotensin II type 1 (AT1) receptor without inhibiting bradykinin metabolism. Phase III data submitted to the FDA showed that losartan 50 to 100 mg daily reduced sitting diastolic blood pressure by approximately 8 to 10 mmHg compared to placebo, with a cough incidence comparable to placebo. The approval label stated that losartan's antihypertensive effect was "substantially present within one week" and reached maximum reduction by three to six weeks.

The same year, the FDA approved losartan combined with hydrochlorothiazide (Hyzaar) under NDA 020387, recognizing that many patients require combination therapy to reach blood pressure targets set by the Joint National Committee guidelines.

Mechanism and Pharmacology on the Label

Losartan binds selectively to the AT1 receptor subtype, blocking the vasoconstrictive and aldosterone-secreting effects of angiotensin II regardless of the synthesis pathway. The current prescribing information notes that losartan and its active carboxylic acid metabolite EXP3174 do not bind or block the AT2 receptor.

EXP3174 is roughly 10 to 40 times more potent than the parent compound at the AT1 receptor, according to in vitro binding studies. The cytochrome P450 2C9 enzyme mediates this conversion, which has clinical relevance: CYP2C9 poor metabolizers produce less EXP3174 and may experience a reduced antihypertensive response. This pharmacogenomic consideration was added to the label as part of the FDA's pharmacogenomics labeling initiative.

Losartan also has a mild uricosuric effect, lowering serum uric acid by approximately 0.4 mg/dL in hypertensive patients. This property is unique among ARBs and has prompted investigation in gout-prone populations, though the effect has not been added as a formal indication.

Label Expansion: Diabetic Nephropathy (2001)

The FDA approved a supplemental NDA for losartan in the treatment of diabetic nephropathy in patients with type 2 diabetes in 2001. The key evidence came from the RENAAL trial (Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan), which randomized 1,513 patients with type 2 diabetes and nephropathy to losartan 50 to 100 mg daily or placebo, on top of conventional antihypertensive therapy.

Over a mean follow-up of 3.4 years, losartan reduced the risk of doubling of serum creatinine by 25% (P=0.006) and the risk of end-stage renal disease by 28% (P=0.002), as published in the New England Journal of Medicine. The benefit was independent of blood pressure reduction. Dr. Barry M. Brenner, the trial's lead investigator, stated: "Losartan conferred significant renal protection in patients with type 2 diabetic nephropathy beyond what could be attributed to blood pressure control alone."

This approval made losartan one of the first ARBs with a labeled renal-protective claim. The American Diabetes Association continues to recommend ARBs (or ACE inhibitors) as first-line therapy for patients with diabetes and albuminuria.

Label Expansion: Stroke-Risk Reduction and the LIFE Trial (2002)

The second major label expansion came in 2002, following publication of the Losartan Intervention For Endpoint reduction in hypertension (LIFE) trial. LIFE randomized 9,193 patients aged 55 to 80 with hypertension and electrocardiographic evidence of left ventricular hypertrophy (LVH) to losartan-based or atenolol-based treatment, with a mean follow-up of 4.8 years.

The primary results, published in The Lancet, showed that losartan reduced the composite endpoint of cardiovascular death, stroke, and myocardial infarction by 13% compared with atenolol (relative risk 0.87, P=0.021). The stroke reduction was particularly striking: a 25% relative risk reduction (P=0.001) despite similar blood pressure lowering between the two arms.

This finding had lasting clinical impact. The FDA updated the Cozaar label to include the indication: "Reduction in the risk of stroke in patients with hypertension and left ventricular hypertrophy." A pre-specified subgroup analysis showed that the benefit was especially pronounced in patients with diabetes, with a 24% reduction in the primary composite endpoint.

The LIFE trial also prompted the European Society of Cardiology to position ARBs as a preferred alternative to beta-blockers for hypertensive patients with LVH, citing the stroke-reduction data from LIFE alongside a broader body of ARB evidence.

Pediatric Labeling

The FDA granted a pediatric indication for losartan in hypertension for children aged 6 years and older in 2004, based on a randomized dose-response trial in 177 children with hypertension. The study demonstrated that losartan 0.7 mg/kg (up to 50 mg) daily significantly reduced blood pressure compared with a very low dose (0.1 mg/kg).

The current label specifies weight-based dosing for pediatric patients and carries a warning that losartan has not been studied in children under 6 years of age or in pediatric patients with a glomerular filtration rate below 30 mL/min/1.73 m². The American Academy of Pediatrics 2017 clinical practice guideline lists losartan among recommended agents for pediatric hypertension management.

Generic Entry and Market Impact

Merck's core patent protection for losartan expired in 2010. The FDA approved the first generic losartan potassium tablets on April 6, 2010, filed by Teva Pharmaceuticals under ANDA 078370. Multiple additional generic manufacturers followed within months, including Aurobindo, Torrent, and Sandoz.

Generic competition reduced the average retail cost significantly. Brand-name Cozaar 50 mg had averaged over $2.50 per tablet; by 2012, generic losartan 50 mg was available for under $0.30 per tablet in many markets. According to the FDA Office of Generic Drugs, losartan has remained one of the most prescribed generic medications in the United States. Data from the CDC National Health and Nutrition Examination Survey consistently show ARBs among the top antihypertensive classes used by U.S. adults, with losartan accounting for the largest ARB prescription volume.

Nitrosamine Impurity Recalls (2018 to 2021)

The most consequential post-market safety event for losartan began in 2018, when the FDA identified N-nitrosodiethylamine (NDEA) and N-nitrosodimethylamine (NDMA) in ARB products manufactured by specific companies. These nitrosamine impurities are probable human carcinogens. The initial recalls targeted valsartan, but by early 2019, losartan tablets from multiple manufacturers were also affected.

The FDA's ARB recall page documented dozens of individual lot recalls between 2018 and 2021. Key manufacturers involved in losartan-specific recalls included Torrent Pharmaceuticals, Hetero Labs, Macleods, and Aurobindo. The root cause was traced to changes in active pharmaceutical ingredient (API) synthesis processes, where certain solvents and reaction conditions favored nitrosamine formation.

Dr. Janet Woodcock, then Acting FDA Commissioner, stated: "The FDA has been working to ensure that manufacturers of ARB drugs assess and prevent the risk of nitrosamine impurities in their products." The FDA subsequently established interim acceptable intake limits for NDMA (96 nanograms per day) and NDEA (26.5 nanograms per day) based on standard cancer risk assessments.

The agency issued a broader industry guidance in 2021 requiring all pharmaceutical manufacturers to evaluate and control nitrosamine impurities across drug products. The FDA Sentinel System was also used to monitor whether patients who had been exposed to contaminated batches showed elevated cancer incidence, though population-level analyses have not identified a statistically significant increase in short-term cancer risk from the exposure levels documented.

Current Label and Boxed Warning

The 2018 label revision for Cozaar carries a boxed warning shared by all drugs affecting the renin-angiotensin system: use during pregnancy can cause fetal injury and death. The warning specifies that losartan should be discontinued as soon as pregnancy is detected. This boxed warning was harmonized across all ARBs and ACE inhibitors following FDA review of post-market adverse event reports.

The current contraindications section also prohibits coadministration with aliskiren in patients with diabetes, based on the ALTITUDE trial (N=8,561), which showed increased rates of hyperkalemia, hypotension, and renal events with dual renin-angiotensin-aldosterone system blockade. The prescribing information lists the three approved indications: hypertension, diabetic nephropathy in type 2 diabetes with an elevated serum creatinine and proteinuria, and stroke-risk reduction in hypertensive patients with LVH. Dosing ranges from 25 mg to 100 mg once daily.

Post-Market Surveillance and Ongoing Safety Data

The FDA Adverse Event Reporting System (FAERS) database contains over three decades of post-market data on losartan. Common adverse events listed on the current label include dizziness, upper respiratory infection, nasal congestion, and back pain. Angioedema occurs rarely but is reported at a lower frequency than with ACE inhibitors, as confirmed by a meta-analysis of ARB safety covering over 50,000 patients.

A 2023 Cochrane systematic review of ARBs for hypertension confirmed that losartan and other ARBs reduce blood pressure with a side-effect profile comparable to placebo for most reported symptoms, apart from the expected effects of blood pressure lowering itself (dizziness, hypotension). Long-term renal outcomes data from RENAAL extension follow-up showed sustained nephroprotective effects, with losartan-treated patients maintaining lower rates of progression to dialysis beyond the original trial period.

The 2024 American Heart Association hypertension guideline lists losartan among first-line agents for stage 1 and stage 2 hypertension, with specific preference given when patients cannot tolerate ACE inhibitor side effects. Current blood pressure targets of <130/80 mmHg for most adults can be achieved with losartan monotherapy in some patients, though many require combination therapy.

Regulatory Comparison: EMA and International Status

Losartan received European regulatory approval through the European Medicines Agency (EMA) in 1994, one year before U.S. approval. The EMA's European public assessment report lists identical core indications: hypertension, diabetic nephropathy in type 2 diabetes, and stroke-risk reduction. The EMA also issued extensive guidance during the nitrosamine recall period, with coordinated testing protocols applied across European manufacturers.

The World Health Organization includes losartan on its Model List of Essential Medicines, classifying it as a core medicine for cardiovascular disease management. This listing supports global access and generic procurement through international health programs.